Alamar Biosciences, Inc. (NASDAQ:ALMR – Get Free Report) major shareholder Corporate Gp Vi Ltd. Qiming sold 100,117 shares of the company’s stock in a transaction dated Wednesday, November 11th. The shares were sold at an average price of $29.38, for a total transaction of $2,941,437.46. Following the completion of the sale, the insider directly owned 157,217 shares of the company’s stock, valued at $4,619,035.46. The trade was a 38.91% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.
Corporate Gp Vi Ltd. Qiming also recently made the following trade(s):
- On Tuesday, November 3rd, Corporate Gp Vi Ltd. Qiming sold 111,313 shares of Alamar Biosciences stock. The stock was sold at an average price of $29.89, for a total transaction of $3,327,145.57.
- On Monday, November 2nd, Corporate Gp Vi Ltd. Qiming sold 43,930 shares of Alamar Biosciences stock. The stock was sold at an average price of $29.84, for a total transaction of $1,310,871.20.
- On Friday, October 30th, Corporate Gp Vi Ltd. Qiming sold 143,706 shares of Alamar Biosciences stock. The stock was sold at an average price of $30.38, for a total value of $4,365,788.28.
- On Wednesday, October 28th, Corporate Gp Vi Ltd. Qiming sold 100,837 shares of Alamar Biosciences stock. The stock was sold at an average price of $32.77, for a total value of $3,304,428.49.
- On Tuesday, October 27th, Corporate Gp Vi Ltd. Qiming sold 84,894 shares of Alamar Biosciences stock. The shares were sold at an average price of $31.39, for a total value of $2,664,822.66.
- On Monday, October 26th, Corporate Gp Vi Ltd. Qiming sold 132,524 shares of Alamar Biosciences stock. The shares were sold at an average price of $30.52, for a total value of $4,044,632.48.
- On Friday, October 23rd, Corporate Gp Vi Ltd. Qiming sold 147,934 shares of Alamar Biosciences stock. The shares were sold at an average price of $30.59, for a total value of $4,525,301.06.
- On Thursday, October 22nd, Corporate Gp Vi Ltd. Qiming sold 133,811 shares of Alamar Biosciences stock. The stock was sold at an average price of $29.33, for a total value of $3,924,676.63.
- On Wednesday, October 21st, Corporate Gp Vi Ltd. Qiming sold 208,815 shares of Alamar Biosciences stock. The shares were sold at an average price of $30.31, for a total value of $6,329,182.65.
- On Tuesday, October 20th, Corporate Gp Vi Ltd. Qiming sold 142,004 shares of Alamar Biosciences stock. The shares were sold at an average price of $27.89, for a total value of $3,960,491.56.
Alamar Biosciences Price Performance
Shares of NASDAQ:ALMR traded down $0.95 during trading on Friday, reaching $30.81. The company had a trading volume of 667,712 shares, compared to its average volume of 745,923. The firm has a market capitalization of $2.14 billion and a price-to-earnings ratio of -14.33. The stock’s fifty day moving average price is $30.25 and its 200 day moving average price is $27.16. Alamar Biosciences, Inc. has a fifty-two week low of $18.84 and a fifty-two week high of $39.61.
Hedge Funds Weigh In On Alamar Biosciences
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Palumbo Wealth Management LLC lifted its holdings in shares of Alamar Biosciences by 16.5% in the 3rd quarter. Palumbo Wealth Management LLC now owns 16,934 shares of the company’s stock valued at $577,000 after buying an additional 2,402 shares during the period. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Alamar Biosciences in the third quarter valued at approximately $196,000. Squarepoint Ops LLC purchased a new stake in shares of Alamar Biosciences in the second quarter valued at approximately $283,000. Sumitomo Mitsui Trust Group Inc. boosted its stake in shares of Alamar Biosciences by 18.5% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 66,913 shares of the company’s stock valued at $2,280,000 after buying an additional 10,461 shares in the last quarter. Finally, Teachers Retirement System of The State of Kentucky acquired a new position in Alamar Biosciences during the third quarter worth $606,000.
Wall Street Analyst Weigh In
Several brokerages have issued reports on ALMR. TD Cowen boosted their price objective on shares of Alamar Biosciences from $34.00 to $36.00 and gave the company a “buy” rating in a research note on Wednesday, November 4th. Stifel Nicolaus upped their price objective on shares of Alamar Biosciences from $28.00 to $32.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. Weiss Ratings upgraded shares of Alamar Biosciences from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, November 4th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Alamar Biosciences from $32.00 to $35.00 and gave the company an “overweight” rating in a report on Tuesday, August 11th. Four investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $33.00.
Check Out Our Latest Report on Alamar Biosciences
About Alamar Biosciences
Alamar Biosciences is a life sciences tools company that develops technologies for measuring proteins in biological samples. Its products are designed to help researchers study disease biology and support the development of tools for earlier disease detection and precision medicine. The company’s offerings include its NULISA platform, which enables sensitive measurement of multiple proteins, and the ARGO HT system, an automated instrument for running assays. Its applications include research into neurodegenerative diseases, cancer and inflammation.
Recommended Stories
- Five stocks we like better than Alamar Biosciences
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Alamar Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alamar Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
